Terbium-161 NCA
GMP grade available
Terbium-161 in aqueous 0.05M HCl is compliant to the highest quality standards of Good Manufacturing Practice (GMP).
Carrier-free lanthanide (NCA) Terbium-161 is produced by neutron activation of enriched Gadolinium-160 using small and medium research reactors.
As a promising radionuclide for Radioligand Therapy, Terbium-161 exhibits comparable chemical characteristics to known radiolanthanides and providing for a bioequivalence creating a similar biodistribution, however a higher cellular absorbed dose is given to lesions and (micro)metastases.
Radiochemistry Unchanged
Terbium-161 provides for comparable chemical characteristics to known radiolanthanides, allowing the utilization of current radiolabeling techniques, but enabling a higher cellular absorbed dose.
Imaging Optimized
Allowing optimization of the SPECT reconstruction parameters, Terbium-161 may provide for higher spatial resolution SPECT imaging, leading to the detection of smaller lesions that provides input for a further optimized treatment plan.
Radiation Safety Improved
Terbium-161 provides for an immediate decrease in dose rate allowing for a significant improvement in general radiation safety. This optimization of radiation safety may extend current treatment room capacity for Radioligand Therapy or allow for outpatient treatment.
Latest news
- Publishing date:
Dejan Čatlaić joined the TerThera team!
Starting in his role as Project Manager, Dejan brings extensive experience in site creation and over a decade of experience in the production of radiopharmaceuticals. As the lead in key projects, Dejan will be responsible for the finalization of our newly built production site and provide support in the production of Terbium-161 GMP.
“I’m really grateful and excited to take on this challenge and looking forward to helping bring the Tb161 production site to completion. What makes it even more special is the chance to reunite with colleagues with whom I’ve already shared great successes in the past. I can’t wait to achieve new milestones together!” said Dejan Čatlaić, Project Manager at TerThera b.v.
- Publishing date:
GMP Terbium-161 product launched by TerThera
TerThera B.V. has officially launched the world’s first GMP-compliant Terbium-161 NCA, setting a new benchmark in the commercial scale production of this promising radionuclide.
- Publishing date:
TerThera reached milestone producing over 200Ci (7.4TBq) Terbium-161
Milestone reached. With the extended geographical reach, we were able to meet the demand for Terbium-161 (Tb-161) on 6 continents by ramping up the production that has led to reaching the threshold 200Ci or 7.4TBq Terbium-161 produced and expedited.
